Press Release: Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised
Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised Paris, July 28, 2023 Q2 2023 sales...
Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised Paris, July 28, 2023 Q2 2023 sales...
BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel...
BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- TrialWire™ Rapid Patient Recruitment Platform, the pay per enrollment recruitment service powered by...
Company Announcement COPENHAGEN, Denmark; July 28, 2023 – Genmab A/S (Nasdaq: GMAB) announced today its preliminary first half 2023 financial...
• Last patient dosed in SPL026-SSRI drug interaction study with data readout anticipated in Q3 2023 • Potential for an...
Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in subjects with Stargardt Disease (STGD1)...
Exercise of Procurement Options of Approximately $113 Million for Oral TPOXX and Approximately $25 Million for IV TPOXX under Current...
Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million2, and long-term deposit at €9.3 million3 as of...
BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel...
Appointment adds Dr. Powchik’s experience in the development of marketed immunotherapeutics to Vaxxinity’s leadership team CAPE CANAVERAL, Fla., July 27,...
REDWOOD CITY, CA / ACCESSWIRE / July 27, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and...
Activities support sustainable supply of Jaguar's botanical drug crofelemer, the active ingredient in the company's FDA-approved human drug Mytesi® and...
CAMBRIDGE, Mass., and DEVENS, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing...
WATERTOWN, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery,...
SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the...
FemBloc® patent application provides additional coverage for Femasys’ therapeutic option for women seeking permanent birth controlATLANTA, July 27, 2023 (GLOBE...
LOS ANGELES, July 27, 2023 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today welcomed two of its newest Board...
Topline data expected in 2024MIAMI, July 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”),...
Combined company to operate as Ayala Pharmaceuticals, Inc. Merger to add a clinical stage oncology asset to Ayala’s portfolio with...
Phase 1-ready device shows 100% success in human functional study of twelve subjects to dateSAN DIEGO, July 27, 2023 (GLOBE...